Overcome Patient-Level Access Barriers For New Medicine

By Ross Maclean, MD and Ann-Louice Bruhn, RN, MSc, MBA

Without market access a novel branded treatment has no commercial viability. Thus, securing access is a business priority. Yet access is typically viewed from the perspective of the biopharma firm. In this article the authors look at access from the patient’s perspective and in doing so identify five aspects of how people get hold of a medicine that should inform commercialization.